Blood cholesterol rise inhibitory composition
A synergistic composition of chitosan with specific materials dramatically enhances the suppression of blood cholesterol rise, effectively inhibiting cholesterol absorption and preventing arteriosclerosis.
Patent Information
- Application Number
- JP2024160037
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-09-17
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2037-06-19
AI Technical Summary
Existing compositions containing chitosan do not sufficiently suppress the rise in blood cholesterol, despite its reported effects.
A composition combining chitosan with specific materials such as resveratrol, lycopene, soy isoflavones, nattokinase, cocoa polyphenols, octacosanol, fucoidan, citrulline, noni leaves, chia seeds, olive fruits, or flaxseeds synergistically enhances the cholesterol-lowering effect.
The combination significantly improves the ability to inhibit cholesterol absorption, thereby preventing arteriosclerosis.
Smart Images

Figure 2024163339000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition having an effect of suppressing an increase in blood cholesterol, and more particularly to a composition having an effect of suppressing an increase in blood cholesterol, which contains chitosan and a specific material.
[0002] Chitosan is known to have various functions for regulating the body, one of which is the suppression of an increase in blood cholesterol, but its effect alone is not necessarily sufficient.
[0003] Other functions of chitosan that have been reported include, for example, an effect of improving serum uric acid levels (see Patent Document 1) and an antioxidant effect (see Patent Document 2). [Prior art documents] [Patent documents]
[0004] [Patent Document 1] JP 2009-120502 A [Patent Document 2] JP 2005-075957 A Summary of the Invention [Problem to be solved by the invention]
[0005] An object of the present invention is to provide a composition having a dramatically improved effect of inhibiting an increase in blood cholesterol level. [Means for solving the problem]
[0006] As a result of extensive research and study into the effect of chitosan in inhibiting an increase in blood cholesterol levels, the inventors discovered that by combining chitosan with a specific material, the effect of inhibiting an increase in blood cholesterol levels can be synergistically improved, and thus completed the present invention.
[0007] That is, the present invention is as follows. [1] A composition for suppressing an increase in blood cholesterol level, comprising chitosan and at least one material selected from the group consisting of the following (a) and (b): (a) at least one functional ingredient selected from resveratrol, lycopene, soy isoflavone, nattokinase, cocoa polyphenol, octacosanol, fucoidan, and citrulline; (b) at least one plant material selected from noni leaves, chia seeds, olive fruits, and flaxseeds; [2] The composition according to [1], which is in the form of a tablet, capsule, powder, granules, or liquid. [3] The composition according to [1] or [2], which is a food composition. Effect of the Invention
[0008] According to the composition of the present invention, the combination of chitosan with a specific material can synergistically improve the effect of inhibiting an increase in blood cholesterol. [Brief description of the drawings]
[0009] [Figure 1] FIG. 2 is a graph showing the blood cholesterol increase inhibitory effect (bile acid binding rate) of the composition of the present invention (chitosan + resveratrol). [Diagram 2] FIG. 1 is a graph showing the blood cholesterol increase inhibitory effect (bile acid binding rate) of the composition of the present invention (chitosan+lycopene). [Diagram 3] FIG. 2 is a graph showing the blood cholesterol increase inhibitory effect (bile acid binding rate) of the composition of the present invention (chitosan + soybean isoflavone). [Figure 4] FIG. 1 is a graph showing the blood cholesterol increase inhibitory effect (bile acid binding rate) of the composition of the present invention (chitosan + nattokinase). [Diagram 5] FIG. 2 is a graph showing the blood cholesterol increase inhibitory effect (bile acid binding rate) of the composition of the present invention (chitosan + cacao polyphenols). [Figure 6]FIG. 2 is a graph showing the blood cholesterol increase inhibitory effect (bile acid binding rate) of the composition of the present invention (chitosan + octacosanol). [Figure 7] FIG. 1 is a graph showing the blood cholesterol increase inhibitory effect (bile acid binding rate) of the composition of the present invention (chitosan + fucoidan). [Figure 8] FIG. 1 is a graph showing the blood cholesterol increase inhibitory effect (bile acid binding rate) of the composition of the present invention (chitosan + citrulline). [Figure 9] FIG. 1 is a graph showing the blood cholesterol increase inhibitory effect (bile acid binding rate) of the composition of the present invention (chitosan + noni leaf). [Figure 10] FIG. 2 is a graph showing the blood cholesterol increase inhibitory effect (bile acid binding rate) of the composition of the present invention (chitosan + chia seed). [Figure 11] FIG. 2 is a graph showing the blood cholesterol increase inhibitory effect (bile acid binding rate) of the composition of the present invention (chitosan + olive fruit). [Figure 12] FIG. 2 is a graph showing the blood cholesterol increase inhibitory effect (bile acid binding rate) of the composition of the present invention (chitosan + flaxseed). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] The composition of the present invention is characterized by containing chitosan and at least one material selected from the group consisting of the following (a) and (b) (hereinafter, sometimes referred to as other material). The materials (a) and (b) used together with chitosan may be used alone or in combination of two or more. When two or more other materials are used in combination, it is preferable to combine other materials that have a high synergistic effect with chitosan.
[0011] According to the composition of the present invention, the combination of chitosan with a specific material can synergistically improve the effect of suppressing the increase in blood cholesterol (LDL cholesterol), and therefore the composition of the present invention is also useful for preventing arteriosclerosis.
[0012] [Chitosan] The chitosan used in the composition of the present invention is a basic dietary fiber having an amino group, and examples thereof include those obtained from the shells of crabs, shrimp, insects, etc., those obtained from the cell walls of mushrooms, filamentous fungi, etc., and those obtained from the midbone (cartilage) of squid. Among these, those obtained from crabs, shrimp, etc. are preferred. The chitosan of the present invention may have chitin remaining in the chitosan chain, or may be in the form of a salt.
[0013] Chitosan can be obtained, for example, by the following method. First, crab shells, shrimp shells, etc. are crushed, and the crushed shells are treated with an acid such as hydrochloric acid to remove calcium. Next, they are treated with an alkali such as caustic soda to remove proteins, and chitin is obtained. This is further treated with an alkali such as caustic soda to obtain chitosan.
[0014] [Other materials] (a) Functional materials In the composition of the present invention, it is preferable to use at least one functional material selected from resveratrol, lycopene, soybean isoflavone, nattokinase, cacao polyphenol, octacosanol, fucoidan, and citrulline together with chitosan.
[0015] (Resveratrol) The resveratrol of the present invention is not particularly limited as long as it is a type of stilbenoid (stilbene derivative) polyphenol and has the systematic name of 3,5,4'-trihydroxy-trans-stilbene. Resveratrol is contained in natural products such as grapes, apple berries, cowberries, and Indian knotweed. In the composition of the present invention, processed products (dried products, crushed products, squeezed juice, extracts, purified products, etc.) of such natural products may be used, or chemically synthesized products may be used.
[0016] (Lycopene) The lycopene of the present invention has the chemical formula C 40 H 56(molecular weight 536.87), there is no particular limitation. Lycopene belongs to the carotenes, a type of carotenoid, and is a red pigment that exhibits an absorption maximum at 474 nm (acetone), and is known to have extremely high antioxidant and whitening effects. Lycopene exists as cis and trans isomers of the conjugated double bond at the center of the molecule, and examples of such isomers include all-trans, 9-cis and 13-cis isomers. In the present invention, lycopene may be any of the above-mentioned isomers.
[0017] Lycopene is naturally contained in natural products such as tomatoes, persimmons, watermelons, pink grapefruits, etc. In the composition of the present invention, processed products (dried products, crushed products, squeezed juice, extracts, purified products, etc.) of such natural products may be used, or chemically synthesized products may be used.
[0018] (Soy Isoflavones) Soybean isoflavone is a kind of flavonoid that is mainly contained in soybean germ. The soybean isoflavone in the present invention may be aglycone or glycoside. In addition, in the composition of the present invention, the soybean isoflavone may be purified, or processed soybean (dried, crushed, squeezed juice, extract, etc.) may be used.
[0019] (Nattokinase) Nattokinase is an enzyme purified from Bacillus subtilis var. natto contained in natto. In the composition of the present invention, the nattokinase may be purified, or a processed product of natto (dried product, crushed product, squeezed juice, extract, etc.) may be used.
[0020] (cocoa polyphenols) Cacao polyphenols are polyphenols contained in cacao beans, which are the raw material for chocolate and cocoa, and are a mixture of compounds (flavanols) mainly consisting of epicatechin and catechin. In the composition of the present invention, the cacao polyphenols may be purified, or processed products of cacao beans (dried products, crushed products, juice, extracts, etc.) may be used.
[0021] (Octacosanol) Octacosanol, also known as octacosyl alcohol, is an alcohol contained in plant leaves and fruit skins such as apples and grapes. In the composition of the present invention, such processed natural products (dried products, crushed products, squeezed juice, extracts, purified products, etc.) may be used, or chemically synthesized products may be used.
[0022] (Fucoidan) Fucoidan is a polysaccharide that is composed mainly of fucose and is bound to sulfuric acid and uronic acid, and is known to have anti-cancer, anti-ulcer, and cholesterol-lowering effects. Fucoidan is contained in seaweed, kelp, wakame, mozuku, and hijiki, and is particularly high in gagome kelp and mozuku, and is preferably used in the present invention. In the composition of the present invention, such natural products may be processed (dried, crushed, squeezed, extracted, purified, etc.), or chemically synthesized products may be used.
[0023] (Citrulline) The citrulline of the present invention may be L-citrulline or D-citrulline, but is preferably L-citrulline.Citrulline can be obtained by chemical synthesis, fermentation, or any other method of production.Citrulline can also be in the form of salt, and salt is not particularly limited as long as it is pharmacologic acceptable salt, and can include, for example, inorganic acid salt, organic acid salt, metal salt, and ammonium salt.
[0024] (b) Plant material In the composition of the present invention, it is preferable to use at least one plant material selected from noni leaves, chia seeds, olive fruits, and flaxseeds together with chitosan.
[0025] These plant materials are preferably used as plant processed products such as dried plants, crushed plants, juices, extracts, etc. Crushed plants can be used in the form of powders, granules, etc. The juices and extracts may be in the form of liquids, but can also be used in the form of pastes or dry powders. Extracts can be obtained by extraction using a suitable solvent, and examples of the solvent that can be used include water (warm water, hot water), ethanol, and aqueous ethanol. Commercially available plant materials may be used.
[0026] (Noni leaves) Noni is an evergreen small tree of the Rubiaceae family, Morinda genus, also known as Yaeyama Aoki (Yaeyama Aoki). Its scientific name is Morinda citrifolia. In the present invention, it is preferable to use crushed Noni leaves.
[0027] (Chia seeds) Chia is an annual plant of the Salvia genus in the Lamiaceae family, and its scientific name is Salvia hispanica. Chia seeds are rich in Ω-3 fatty acids. In the present invention, it is preferable to use an ethanol or hydroethanol extract of chia seeds.
[0028] (Olive fruit) Olive is an evergreen tree of the Oleaceae family, and its scientific name is Olea europaea. Olive fruits contain healthy components such as oleic acid and vitamin E, and are used to produce olive oil and pickles. In the present invention, it is preferable to use fruit juice squeezed from olive fruits, which can be appropriately concentrated before use.
[0029] (linseed) Flax is an annual plant of the Linaceae family, and its scientific name is Linum usitatissimum. Flaxseed is the seed of the flax plant, and is rich in α-linolenic acid, lignans, and dietary fiber, and has strong antioxidant properties. In the present invention, it is preferable to use ground flaxseed.
[0030] The composition of the present invention has the effect of suppressing an increase in blood cholesterol, and can be used, for example, as so-called health foods such as pharmaceuticals (including quasi-drugs), functional foods such as specified health foods, nutritional functional foods, and functional food whose efficacy has been approved by a designated organization, as well as general foods, food additives, feed, etc.
[0031] The composition of the present invention can be used as a composition for suppressing an increase in blood cholesterol, and such a food for suppressing an increase in blood cholesterol is not particularly limited as long as it contains chitosan and a specified material and can be distinguished from other products in terms of being used to suppress an increase in blood cholesterol. For example, the present invention includes a product that indicates that the product has an inhibitory effect on an increase in blood cholesterol on the main body, packaging, instruction manual, or advertising material of the product of the present invention. The composition for suppressing an increase in blood cholesterol of the present invention is not limited to a product that indicates the combined components of the present invention (chitosan and other specified materials) as active ingredients for suppressing an increase in blood cholesterol on the product packaging, etc. For example, the active ingredient may not be specified, and the product may indicate only chitosan as an active ingredient.
[0032] Specifically, examples of the composition of the present invention for suppressing an increase in blood cholesterol include pharmaceuticals (including quasi-drugs) and so-called health foods. Examples of so-called health foods include those labeled as "suppresses the increase in cholesterol," "for those concerned about cholesterol," "suppresses cholesterol absorption," "for those with high cholesterol," etc.
[0033] Examples of the form of the composition of the present invention include tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, rounds, pastes, creams, caplets, gels, chewables, and sticks. Among these, tablets, capsules, powders, granules, and liquids are particularly preferred. Specific examples include supplements, containerized beverages filled in PET bottles, cans, bottles, and the like, instant beverages to be dissolved in water (hot water), milk, fruit juice, green juice, and the like, and food additives. These are preferred because they are easy to drink during meals and can increase palatability.
[0034] The content of chitosan and other materials (components of the present invention) in the composition of the present invention may be appropriately determined within the range in which the desired effect is exhibited.
[0035] In general, when the composition of the present invention is a pharmaceutical or supplement, the components of the present invention are contained in an amount of preferably 0.1 to 100 mass% of the total, calculated as dry mass, more preferably 1 to 85 mass%, and even more preferably 5 to 70 mass%.
[0036] When the composition of the present invention is a packaged beverage, the components of the present invention are preferably contained in an amount of 0.0001 to 3 mass% of the total, more preferably 0.001 to 1 mass%, and even more preferably 0.01 to 0.5 mass%.
[0037] Furthermore, when the composition of the present invention is an instant beverage, the component of the present invention is contained in an amount of preferably 0.001 to 80 mass%, more preferably 0.005 to 70 mass%, and even more preferably 0.1 to 60 mass%, of the total mass calculated on a dry mass basis.
[0038] In order to more effectively exert the effects of the present invention, the components of the present invention are preferably contained in an amount of 80% or more of the total composition of the present invention, calculated on a dry mass basis, more preferably 90% or more, even more preferably 95% or more, and particularly preferably 100%.
[0039] The amount of intake of the composition of the present invention is not particularly limited, but from the viewpoint of more significantly exerting the effect of the present invention, it is preferable to take the component of the present invention in an amount of 10 mg / day or more, more preferably 100 mg / day or more, and even more preferably 800 mg / day or more. The composition of the present invention can be stored as a daily amount in one container or divided into, for example, 2 to 3 multiple containers so that the daily intake is the above-mentioned amount.
[0040] The blending mass ratio of chitosan to other materials, calculated on a dry mass basis, is preferably in the range of 0.5:1 to 2000:1, more preferably in the range of 0.75:1 to 1000:1, further preferably in the range of 1:1 to 500:1, and particularly preferably in the range of 1:1 to 300:1. By having the blending ratio of chitosan to other materials in the above range, the effects of the present invention can be more effectively exhibited.
[0041] The composition of the present invention can be produced by a known method by adding other components other than the components of the present invention as necessary. Examples of other components other than the components of the present invention include vitamins such as water-soluble vitamins (vitamin B1, B2, B3, B5, B6, B12, B13, B15, B17, biotin, choline, folic acid, inositol, PABA, vitamin C, vitamin P) and oil-soluble vitamins (vitamins A, D, E, K); minerals such as calcium, magnesium, phosphorus, and iron; sulfur-containing compounds contained in taurine and garlic; flavanoids or flavonoids such as hesperidin and quercetin; proteins such as collagen; peptides; amino acids; animal fats and oils; vegetable fats and oils; crushed products or extracts of animals and plants, etc. EXAMPLES
[0042] The present invention will be described below with reference to examples. (Sample preparation) The test substances were added at a concentration of 0.05% (W / V) ("chitosan 500μg / mL", "other materials 500μg / mL", "chitosan 450μg / mL + other materials 50μg / mL") to 6mL of postprandial artificial intestinal fluid (FeSSIF: 15mM sodium taurocholate, 3.75mM lecithin, 144mM acetic acid, 101mM sodium hydroxide, 173mM sodium chloride, pH 5.0) warmed to 37℃ and vortexed. The mixture was then warmed in a 37℃ water bath for 30 minutes while shaking at 100 rpm. As a control, 6mL of postprandial artificial intestinal fluid was warmed in a 37℃ water bath for 30 minutes while shaking at 100 rpm.
[0043] After warming for 30 minutes, the mixture was centrifuged at 2000 rpm for 10 minutes.
[0044] 3 mL of the supernatant was taken without sucking up the precipitate (test substance), and an equal volume of ethyl acetate was added, followed by vortexing for 30 seconds. After vortexing, the mixture was centrifuged at 2000 rpm for 10 minutes.
[0045] The upper layer (1.5 mL) of the liquid was transferred to a new Falcon and evaporated to dryness using a centrifugal evaporator.
[0046] To the dried product, 600 μL of 2-propanol was added, and the mixture was subjected to ultrasonic waves for 10 minutes.
[0047] Thereafter, the mixture was centrifuged at 800 rpm for 3 minutes, and the supernatant was collected in a 1.5 mL tube to obtain a sample.
[0048] The following test substances were used: An extract from crab was used as chitosan. As the noni, sterilized and crushed noni leaves were used. A 60% EtOH extract was used as chia seed. As for the olive, a concentrated extract of fruit juice (squeezed fruit juice) was used. Roasted powder was used as flaxseed. Resveratrol was extracted from grapes. The fucoidan used was refined powder of Okinawa mozuku seaweed. Lycopene, soybean isoflavone, nattokinase, cacao polyphenol, octacosanol and citrulline were used as commercially available products.
[0049] (Measurement of bile acid concentration) The bile acid concentration in the sample was measured using a Wako Total Bile Acid Test in the following manner.
[0050] 62.5 μL of enzyme solution was added to 25 μL of sample, mixed thoroughly, and then heated at 37° C. for 10 minutes. 62.5 μL of reaction stop solution was then added, mixed thoroughly, and the absorbance at 560 nm was measured. In addition, 62.5 μL of blank enzyme solution was added to 25 μL of sample, and reacted in the same manner to serve as a sample blank.
[0051] 62.5μL of enzyme solution was added to 25μL of aqueous propanol solution with 2-propanol concentration adjusted to 10, 20, 30, 40, 50μmol / L, mixed well, and heated at 37℃ for 10 minutes. Then, 62.5μL of reaction stop solution was added, mixed well, absorbance at 560nm was measured, and a calibration curve was created. In addition, 62.5μL of blank enzyme solution was added to 25μL of aqueous propanol solution with 2-propanol concentration adjusted to 10μmol / L, and reacted in the same manner, and this was used as the standard blank.
[0052] The bile acid concentration (μmol / L) of the sample was calculated from the calibration curve, and the relative value (%) was calculated with the control taken as 100%.
[0053] The results are shown in Figures 1 to 12. Each figure shows the results for each added component: "chitosan alone", "other material alone", and "chitosan + other material added". The concentration unit of the added components is μg / mL in all graphs. The vertical axis shows the bile acid binding rate (what percentage of the bile acid in the control (100%) was adsorbed).
[0054] As shown in Figures 1 to 12, the bile acid binding rate was synergistically improved by combining chitosan with a specific material. Therefore, it can be seen that the effect of suppressing the rise in blood cholesterol by inhibiting cholesterol absorption in the body is dramatically improved by combining chitosan with a specific material.
[0055] [Example 2] (Production of tablets) Five tablets (250 mg) were prepared consisting of the following ingredients:
[0056] Chitosan 70% Resveratrol 0.5% Cocoa polyphenols 0.5% Lycopene 0.5% Calcium stearate 2% Silicon dioxide 2% Reduced maltose 24.5% [Example 3] (Production of tablets) Three tablets (350 mg) were prepared consisting of the following ingredients:
[0057] Chitosan 86% Soy Isoflavones 1% Nattokinase 1% Octacosanol 1% Sucrose fatty acid ester 7% Reduced maltose 3% Pullulan 1%
[0058] The tablets are to be taken once or two or three times a day with water.
[0059] [Example 4] (Production of capsules) The following mixture was packed into a hard capsule to prepare a capsule formulation (300 mg).
[0060] Chitosan 40% Resveratrol 1% Lycopene 1% Soy Isoflavones 1% Noni Leaf 1% Chia seeds 1% Olive Juice Extract 1% Nattokinase 1% Cocoa polyphenols 1% Flaxseed 1% Octacosanol 1% Fucoidan 1% Citrulline 1% Lactic acid bacteria 10% Cellulose 36% Silicon dioxide 2%
[0061] Take 4 capsules of the above once a day or 2 to 4 divided doses with water.
[0062] [Example 5] (Production of granules) The following ingredients were mixed and prepared into granules (3000 mg) in a conventional manner.
[0063] Chitosan 10% Citrulline 10% Aspartame 5% Thiamine hydrochloride 0.33% Riboflavin 0.33% Vitamin B6 0.17% Cyanocobalamin 6 0.17% Fragrance 0.17% Reduced Palatinose 6.67% Calcium stearate 3.33% Hydroxypropyl cellulose Remainder
[0064] [Example 6] (Production of instant powder) The following ingredients were mixed together and prepared into an instant powder (2 g) in a conventional manner.
[0065] Chitosan 50% Fucoidan 5% Olive Juice Extract 5% Aspartame 8% Stevia 3% Malic acid 0.5% Pigment preparation 0.5% Fragrance 0.25% Polydextrose Remainder
[0066] [Example 7] (Production of liquid formulation) A liquid formulation (200 mL) consisting of the following components was prepared.
[0067] Chitosan 0.62% Noni Leaf 0.05% Chia seeds 0.05% Flaxseed 0.05% Pu-erh tea processed food 0.13% Jasmine tea processed food 0.15% Fructooligosaccharides 0.075% Vitamin C 0.25% Water remaining [Industrial Applicability]
[0068] INDUSTRIAL APPLICABILITY The composition of the present invention has an effect of suppressing an increase in blood cholesterol and is therefore highly useful industrially.
Claims
[Claim 1] Chitosan and A composition for suppressing an increase in blood cholesterol, comprising at least one member selected from the group consisting of soybean isoflavone and lycopene.
Citation Information
Patent Citations
Antiobestic drug and method for producing the same
JP2001302519A
Health food
JP2002272416A
Bioactivation apparatus
JP2004243099A
Bile acid adsorbent
JP2011116679A
Compositions and products containing enantiomeric equol, and production methods thereof
JP2016053027A
